User profiles for Serdar Farhan

Serdar Farhan

Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, NY, NY
Verified email at mountsinai.org
Cited by 2771

Everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents

…, AS Kini, SK Sharma, M Faggioni, S Farhan… - Journal of the American …, 2017 - jacc.org
Background : Recent evidence suggests that bioresorbable vascular scaffolds (BVS) are
associated with an excess of thrombotic complications compared with metallic everolimus-…

Pathophysiology, Echocardiographic Diagnosis, and Treatment of Atrial Functional Mitral Regurgitation: JACC State-of-the-Art Review

S Farhan, JJ Silbiger, JL Halperin, L Zhang… - Journal of the American …, 2022 - jacc.org
The conventional view holds that functional mitral regurgitation (MR) is caused by restriction
of leaflet motion resulting from displacement of the papillary muscle-bearing segments of …

Prothrombotic milieu, thrombotic events and prophylactic anticoagulation in hospitalized COVID-19 positive patients: a review

MJ Cryer, S Farhan, CC Kaufmann… - Clinical and Applied …, 2022 - journals.sagepub.com
The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in significant morbidity
and mortality worldwide. Although initial reports concentrated on severe respiratory illness, …

Increased intramyocellular lipid concentration identifies impaired glucose metabolism in women with previous gestational diabetes

…, M Krssak, C Winzer, G Pacini, A Tura, S Farhan… - Diabetes, 2003 - Am Diabetes Assoc
Women with previous gestational diabetes (pGDM) are frequently insulin-resistant, which
could relate to intramyocellular lipid content (IMCL). IMCL were measured with 1 H nuclear …

[HTML][HTML] Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome

…, I Tentzeris, R Jarai, KM Katsaros, S Farhan… - PloS one, 2014 - journals.plos.org
Objectives ST2 is a receptor for interleukin (IL)-33. We investigated an association of soluble
ST2 (sST2) and IL-33 serum levels with different clinical stages of coronary artery disease. …

Coronary calcification and long-term outcomes according to drug-eluting stent generation

…, M Liu, S Sorrentino, G Giustino, S Farhan… - Cardiovascular …, 2020 - jacc.org
Objectives The aim of this study was to evaluate the long-term impact of coronary artery
calcification (CAC) on outcomes after percutaneous coronary intervention and the respective …

Complementary role of copeptin and high‐sensitivity troponin in predicting outcome in patients with stable chronic heart failure

I Tentzeris, R Jarai, S Farhan… - European journal of …, 2011 - Wiley Online Library
Aims Copeptin, the C‐terminal part of the vasopressin pro‐hormone, is elevated after myocardial
infarction and predicts adverse outcome. In the present study we investigated whether …

Residual inflammatory risk in patients with low LDL cholesterol levels undergoing percutaneous coronary intervention

…, M Aquino, S Sorrentino, G Giustino, S Farhan… - Journal of the American …, 2019 - jacc.org
Background : Data on the impact of residual inflammatory risk (RIR) in patients undergoing
percutaneous coronary intervention (PCI) with baseline low-density lipoprotein cholesterol (…

Ticagrelor with or without aspirin after PCI: the TWILIGHT platelet substudy

…, AS Kini, S Sartori, L Joyce, B Vogel, S Farhan… - Journal of the American …, 2020 - jacc.org
Background An evolving strategy in the setting of percutaneous coronary intervention (PCI)
involves withdrawal of acetylsalicylic acid (ASA), or aspirin, while maintaining P2Y 12 …

Sex differences among patients with high risk receiving ticagrelor with or without aspirin after percutaneous coronary intervention: a subgroup analysis of the …

…, S Sartori, SK Sharma, DJ Angiolillo, S Farhan… - JAMA …, 2021 - jamanetwork.com
Importance Shortened dual antiplatelet therapy followed by potent P2Y12 receptor inhibitor
monotherapy reduces bleeding without increasing ischemic events after percutaneous …